Pfizer agrees $14bn deal for cancer drug firmPfizer, beating out numerous other bidders, said it agreed to buy US cancer drug company Medivation for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. Medivati More… |
Pfizer nears $14bn deal for cancer drug firmPfizer is in advanced talks to acquire US cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, a person familiar with the matter said on Sunday. Pfizer has so far prevailed in the a More… |
Pfizer nears $14bn deal for cancer drug firmPfizer is in advanced talks to acquire US cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, a person familiar with the matter said on Sunday. Pfizer has so far prevailed in the a More… |
John Hopkins says develops anticancer drugScientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel - undetected by normal cells - through the bloodstream until activated by specific cancer proteins. More… |
Cheaper Roche cancer drug as good as LucentisAvastin, a cancer drug made by Roche Holding, was about as effective as the company's far more expensive eye drug, Lucentis, at preventing vision loss in people with age-related macular degeneration, the New York Times reported. The tw More… |